No Reflow after Primary PCI in STEMI: An Angiographic Analysis of the TOTAL Study

In the early days of percutaneous coronary intervention (PCI) in patients with ST elevation acute myocardial infarction (STEMI), no reflow phenomenon was known as an indicator of the worst possible outcomes in terms of left ventricular remodeling, infarct size, ejection fraction and mortality, at long term. 

Fenómeno de no reflow luego de ATC primaria en IAMCEST

The TOTAL study (Routine Aspiration Thrombectomy with PCI Versus PCI Alone in Patients With STEMI Undergoing Primary PCI), comparing manual thrombus aspiration vs. primary PCI alone, did no show significant differences as regards cardiovascular death, repeat MI, cardiogenic shock or NYHA class IV cardiac failure. However, there was increased risk of stroke in the manual thrombectomy group. 

The aim of this post hoc analysis from the multicenter, randomized TOTAL study, was to assess the effect of manual thrombectomy on no reflow outcomes across different subgroups. The study also looked at the link between no reflow and major cardiovascular events at one year, and sought to determine the clinical predictors of no reflow. 

Primary end point was the composite of cardiovascular death, repeat MI, cardiogenic shock and NYHA class IV cardiac failure. Secondary end point included all-cause mortality, rehospitalization for any cause, and stent thrombosis. 

Read also: Mitral Valve Edge to Edge Repair for Papillary Muscle Rupture after Acute Myocardial Infarction.

The analysis included 1800 patients, 10.9% presenting no reflow. Patients in this group were older (64,4 vs 60,8 p <0,01), and mostly men. They more often presented a higher class of Killip Kimball, lower TIMI flow before PCI and less use of direct stenting. 

Patients randomized to manual thrombectomy presented 10,7% no reflow rate, while the PCI group presented 11,1% rate (odds ratio [OR] 0,95, CI 95%: 0,71-1,28; p = 0,76). Patients undergoing direct stenting, in the thrombectomy group, showed a lower incidence of no reflow vs. the PCI group (5,1% vs 9,7%, OR 0,50, CI 95%: 0,26-0,96).

Read also: Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

At one year, patients experiencing no reflow had a 70% increased relative risk of primary end point (15,8% vs 6,3%, HR 1,70, CI 95%: 1,13-2,56; p = 0,01). Also, no reflow was associated with higher risk of cardiogenic shock (8,2% vs 1,7%, HR 2,20, CI 95%: 1,14-4,24, p = 0,02). No flow predictors were identified as: age (OR 1,25, CI 95%: 1,09-1,42; p = 0,001), TIMI flow 3 prior PCI (OR 0,33, CI 95%: 0,19-0,56; p < 0,0001) and direct stenting (OR 0,66, CI 95%: 0,45-0,95, p = 0,03).

Conclusion

This analysis has shown that manual thrombectomy did not reduce no reflow in all patients, but when combined with direct stenting there might be synergy. No reflow is associated with increased adverse clinical events. More studies are required to better assess the link between no reflow and direct stenting. 

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: No-reflow after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: an angiographic core laboratory analysis of the TOTAL Trial.

Reference: Marc-André d’Entremont  MD, MPH et al EuroIntervention 2023;19.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....